Literature DB >> 29053957

CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation.

Isabel C Lopez-Mejia1, Sylviane Lagarrigue2, Albert Giralt3, Laia Martinez-Carreres3, Nadège Zanou4, Pierre-Damien Denechaud1, Judit Castillo-Armengol3, Carine Chavey5, Meritxell Orpinell2, Brigitte Delacuisine1, Anita Nasrallah3, Caterina Collodet6, Lianjun Zhang7, Benoît Viollet8, D Grahame Hardie9, Lluis Fajas10.   

Abstract

The roles of CDK4 in the cell cycle have been extensively studied, but less is known about the mechanisms underlying the metabolic regulation by CDK4. Here, we report that CDK4 promotes anaerobic glycolysis and represses fatty acid oxidation in mouse embryonic fibroblasts (MEFs) by targeting the AMP-activated protein kinase (AMPK). We also show that fatty acid oxidation (FAO) is specifically induced by AMPK complexes containing the α2 subunit. Moreover, we report that CDK4 represses FAO through direct phosphorylation and inhibition of AMPKα2. The expression of non-phosphorylatable AMPKα2 mutants, or the use of a CDK4 inhibitor, increased FAO rates in MEFs and myotubes. In addition, Cdk4-/- mice have increased oxidative metabolism and exercise capacity. Inhibition of CDK4 mimicked these alterations in normal mice, but not when skeletal muscle was AMPK deficient. This novel mechanism explains how CDK4 promotes anabolism by blocking catabolic processes (FAO) that are activated by AMPK. Crown
Copyright © 2017. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK; CDK4; FAO; metabolism; mitochondria

Mesh:

Substances:

Year:  2017        PMID: 29053957     DOI: 10.1016/j.molcel.2017.09.034

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  21 in total

Review 1.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  CDKN2A/p16INK4a suppresses hepatic fatty acid oxidation through the AMPKα2-SIRT1-PPARα signaling pathway.

Authors:  Yann Deleye; Alexia Karen Cotte; Sarah Anissa Hannou; Nathalie Hennuyer; Lucie Bernard; Bruno Derudas; Sandrine Caron; Vanessa Legry; Emmanuelle Vallez; Emilie Dorchies; Nathalie Martin; Steve Lancel; Jean Sébastien Annicotte; Kadiombo Bantubungi; Albin Pourtier; Violeta Raverdy; François Pattou; Philippe Lefebvre; Corinne Abbadie; Bart Staels; Joel T Haas; Réjane Paumelle
Journal:  J Biol Chem       Date:  2020-10-09       Impact factor: 5.157

3.  CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival.

Authors:  Laia Martínez-Carreres; Julien Puyal; Lucía C Leal-Esteban; Meritxell Orpinell; Judit Castillo-Armengol; Albert Giralt; Oleksandr Dergai; Catherine Moret; Valentin Barquissau; Anita Nasrallah; Angélique Pabois; Lianjun Zhang; Pedro Romero; Isabel C Lopez-Mejia; Lluis Fajas
Journal:  Cancer Res       Date:  2019-08-08       Impact factor: 12.701

4.  Personalized phosphoproteomics identifies functional signaling.

Authors:  Elise J Needham; Janne R Hingst; Benjamin L Parker; Kaitlin R Morrison; Guang Yang; Johan Onslev; Jonas M Kristensen; Kurt Højlund; Naomi X Y Ling; Jonathan S Oakhill; Erik A Richter; Bente Kiens; Janni Petersen; Christian Pehmøller; David E James; Jørgen F P Wojtaszewski; Sean J Humphrey
Journal:  Nat Biotechnol       Date:  2021-12-02       Impact factor: 54.908

Review 5.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

Review 6.  Immunomodulation by anticancer cell cycle inhibitors.

Authors:  Giulia Petroni; Silvia C Formenti; Selina Chen-Kiang; Lorenzo Galluzzi
Journal:  Nat Rev Immunol       Date:  2020-04-28       Impact factor: 53.106

Review 7.  Fueling the Cycle: CDKs in Carbon and Energy Metabolism.

Authors:  Maria Solaki; Jennifer C Ewald
Journal:  Front Cell Dev Biol       Date:  2018-08-17

8.  CDK4, a new metabolic sensor that antagonizes AMPK.

Authors:  L Fajas; I C Lopez-Mejia
Journal:  Mol Cell Oncol       Date:  2018-05-16

9.  ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness.

Authors:  Qingyu Luo; Xiaowei Wu; Wan Chang; Pengfei Zhao; Yabing Nan; Xiaolin Zhu; Jonathan P Katz; Dan Su; Zhihua Liu
Journal:  Cell Death Differ       Date:  2019-12-12       Impact factor: 15.828

10.  A CRISPR knockout negative screen reveals synergy between CDKs inhibitor and metformin in the treatment of human cancer in vitro and in vivo.

Authors:  Yarui Ma; Qing Zhu; Junbo Liang; Yifei Li; Mo Li; Ying Zhang; Xiaobing Wang; Yixin Zeng; Yuchen Jiao
Journal:  Signal Transduct Target Ther       Date:  2020-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.